FDA panel: cough meds should stay over-the-counter
A panel of medical experts said Tuesday that cough medicines like Robitussin and Nyquil should continue to be sold over-the-counter, despite increased abuse among teenagers that has prompted calls to restrict sales of the products.
The Food and Drug Administration panel voted 15-9 against a proposal that would require a doctor's note to buy medicines containing dextromethorphan, an ingredient found in more than 100 over-the-counter medications.
The FDA is not bound to follow the group's advice, though it often does. Specifically, panelists were asked if the ingredient should be "scheduled," a regulatory move designed to decrease access to drugs with high potential for abuse.
"For me there was no data to show us that scheduling this product would decrease abuse," said panelist Janet Engle, professor and department head of pharmacy practice at the University of Illinois.
- As Medicare Advantage Cuts Loom, Disagreement Over Program's Stability
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- 3 Management Lessons from a Supermarket Debacle
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- Centralizing the Revenue Cycle Protects the Bottom Line
- CA Fines 8 Hospitals for Medical Errors
- Revenue Cycles Get a Boost from Simple JPEG Files
- IOM Identifies GME Problems, Calls for Finance Changes
- Doctors Feel Pressure to Accept Risk-based Reimbursement
- Employers Weigh Risks, Benefits of Private Exchanges